Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.
Revolution Medicines recently received a major endorsement from the FDA with the designation of its RASONQUE drug as a breakthrough therapy. This could potentially accelerate the development and market launch of the drug for metastatic pancreatic cancer patients. However, the company's stock has skyrocketed by 330% in the last year, indicating that much of the positive sentiment has already been priced into the share price.
For investors seeking exposure to Revolution Medicines, an alternative option is to invest in Royalty Pharma, which offers a more diversified portfolio of pharmaceutical products from various drug makers. This strategy provides a way to spread risk across multiple companies and offerings within the pharmaceutical industry.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
